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Rhabdoid tumour predisposition syndrome (RTPS) is a rare syndrome caused by inheritance of a mutated INI1 gene for which only
two multigeneration families have been reported. To further characterise the genotype and phenotype of RTPS, we present a third
family in which at least three cousins developed an atypical teratoid/rhabdoid tumour (AT/RT) at a young age. Two of these patients
showed unusual long survival, and one of these developed an intracranial meningioma and a myoepithelioma of the lip in adulthood.
Mutation analysis of INI1 revealed a germline G4A mutation in the donor splice site of exon 4 (c.500þ1G4A) in the patients and
in their unaffected fathers. This mutation prevents normal splicing and concomitantly generates a stop codon, resulting in nonsense-
mediated mRNA decay. Biallelic inactivation of INI1 in the tumours, except for the meningioma, was confirmed by absence of nuclear
INI1-protein staining. The myoepithelioma of one of the patients carried an identical somatic rearrangement in the NF2 gene as the
AT/RT, indicating that both tumours originated from a common precursor cell. In conclusion, this study demonstrates for the first
time transmission of a germline INI1-mutation in a RTPS family via nonpenetrant males, long-term survival of two members of this
family with an AT/RT, and involvement of INI1 in the pathogenesis of myoepithelioma.
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High-grade malignant brain tumours (MBTs) of childhood include
medulloblastoma, primitive neuro-ectodermal tumour, anaplastic
astrocytoma, glioblastoma, anaplastic ependymoma, atypical
teratoid/rhabdoid tumour (AT/RT), and choroid plexus carcinoma
(CPC) (Kalifa and Grill, 2005). Although most of these tumours are
sporadic, familial cases have been described in which inherited
germline mutations in tumour suppressor genes predispose to
their development. Germline mutations in PTCH and TP53 are
known to be involved in the familial occurrence of medulloblastoma
in childhood in Gorlin syndrome (Johnson et al, 1996) and of
various types of brain tumours in Li-Fraumeni syndrome
(Frebourg et al, 1995). The familial occurrence of ependymomas
has been well documented, but the predisposing gene remains to
be identified (Dimopoulos et al, 2006). Familial cases of AT/RT or
CPC are very rare. Until now, two families have been described in
which the development of these malignant childhood brain
tumours correlated with the inheritance in two or more genera-
tions of a mutation in the INI1/hSNF5/BAF47/SMARCB1 gene on
chromosome 22 (Taylor et al, 2000; Janson et al, 2006). This
tumour suppressor gene encodes INI1, which is a core subunit of
the chromatin remodelling SWI/SNF complex (Wang et al, 1996;
Phelan et al, 1999). In one family, an 18-month-old girl presented
with a cerebellar rhabdoid tumour with an INI1 exon 7 donor-
splice site mutation, which she inherited from her unaffected
carrier mother. A brother of the latter died at the age of 2 years of a
tumour diagnosed as CPC with the same mutation (Taylor et al,
2000). In the other family, two half-brothers each developed an
AT/RT at a young age and inherited an INI1 insertion mutation in
exon 4 from their unaffected carrier mother. Their maternal half-
uncle, who was diagnosed with a medulloblastoma and a renal
rhabdoid tumour, died at 2 years of age, suggesting that he
inherited the same mutation, although this could not be studied
(Janson et al, 2006).
Here, we present an extended molecular analysis of a previously
reported family in which four cousins were affected with an MBT
at young age (Hulsebos et al, 1999). These tumours were originally
classified as anaplastic ependymomas (Nijssen et al, 1994).
However, because of the previously documented involvement of
chromosome 22 in the inheritance of the predisposition to these
tumours (Hulsebos et al, 1999) and the possibility of misclassifica-
tion, we investigated whether these anaplastic ependymomas were
in fact AT/RTs. This proved to be the case, as we concluded from
re-evaluation of their histopathology and from mutation and
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sexpression analysis of the INI1 gene in three of these tumours.
In addition, one of the patients developed a meningioma and a
myoepithelioma in adulthood.
PATIENTS AND METHODS
Patient material
Written informed consent was obtained from patient III-1 (for
pedigree see Figure 1). Each of the four cousins developed an MBT
at a young age (o5 years). After removal of the tumour, patient
III-1 received adjuvant chemotherapy (methotrexate, vincristine,
and prednisolone) followed by craniospinal radiotherapy
(3300cGy in 22 doses) with a boost of 2100cGy on the location
of the tumour. He developed an intracranial meningioma and a
myoepithelioma of the lip at, respectively, 25 and 26 years of age.
Patient III-4 developed a recurrent brain tumour almost 2 years
after removal of the primary brain tumour and treatment with
chemotherapy (vincristine, procarbazine, and methotrexate). The
sister of the paternal grandfather (I-1) of the four cousins died of
an uncharacterised brain tumour at the age of 2 years. The clinical
findings for the patients are summarised in Table 1.
Freshly frozen tumour tissue was only available from the
meningioma of patient III-1 Formalin-fixed and paraffin-embedded
tumour tissue was available from the other tumours.
DNA and RNA samples
Tumour DNA was extracted using commercially available kits
(QIAGEN, Venlo, The Netherlands). Extraction of constitutional
DNA from blood leukocytes was performed as described
previously (Hulsebos et al, 1999).
Microsatellite analysis
Microsatellite markers used for haplotype analysis of family
members and loss of heterozygosity (LOH) analysis in tumours
were, ordered from 22cen to 22qter, D22S420, D22S427, D22S941,
D22S311, D22S446, D22S539, D22S686, D22S303, D22S257,
D22S345, D22S156, RH13801, D22S925, D22S926, D22S419,
D22S421, D22S1164, D22S429, D22S1148, D22S310, D22S1167,
D22S1163, D22S1150, nf2C3.1, D22S929, nf2CAV, D22S1176,
D22S280, D22S284, D22S419, D22S1165, D22S1171, D22S274,
D22S1169, D22S1145. Because of substantial degradation of
template DNA, reliable determination of the allele status of
markers generating polymerase chain reaction (PCR) products
longer than 150bp could not be performed for the MBTs of III-1
and III-3 and for the recurrent tumour of III-4. Primer sequences
and amplification conditions were taken from the Genome
Database at http://www.gdb.org/ or from Legoix et al (1999).
Polymerase chain reaction reactions were performed essentially as
described before (Bijlsma et al, 1995).
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Figure 1 Haplotyping of family members and LOH analysis of tumours using microsatellite markers from chromosome 22. Patients with the germline INI-
mutation are represented by black symbols and proven nonexpressing carriers of this mutation by dotted symbols. Haplotypes were constructed assuming
minimal numbers of recombinations. Haplotypes for the grandfather (between brackets) were inferred. N: noninferred marker allele. MBT-1, MBT-3, and
MBT-4(R) are the marker alleles retained in the MBT of patients III-1, III-3, and III-4 (R, recurrent tumour), respectively. M-1 and My-1 represent marker
alleles retained in meningioma and myoepithelioma of patient III-1, respectively.
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sproducts were separated on 6% acrylamide denaturing gels and
visualised with autoradiography.
Mutation analysis
The INI1 and NF2 genes were sequenced by using genomic DNA as
substrate for amplification by PCR. Primer sequences for mutation
analysis of the 9 INI1 exons and the 17 NF2 exons have been given
previously (Hulsebos et al, 2007). In degraded DNA samples, the
exon 4–intron 4 junction region of INI1 was sequenced using
forward primer 50-catgctccacaaccatcaac-30 and reverse primer
50-aactgaaacgtgctggagaac-30, generating a PCR-product of 131bp.
Denaturing high-performance liquid chromatography
The exon 4–intron 4 junction region of INI1 was amplified with
forward primer 50-ggatcaggtcctatactgac-30 and reverse primer
50-aactgaaacgtgctggagaac-30, generating a product of 248bp.
Polymerase chain reaction products were analysed on an Agilent
1100 system (Agilent, Amstelveen, The Netherlands) equipped
with a Helix DNA column (Varian, Middelburg, The Netherlands).
Denaturing high-performance liquid chromatography (DHPLC)
running conditions are available upon request.
Multiple ligation-dependent probe amplification
Multiple ligation-dependent probe amplification (MLPA) analysis
of the NF2 gene was performed using the SALSA P044 NF2 MLPA
Kit according to the instructions of the manufacturer (MRC-
Holland, Amsterdam, The Netherlands).
Immunohistochemical analysis
Immunohistochemical analysis of the INI1 protein was performed
using a BAF47/INI1 antibody (BD Transduction Laboratories,
Franklin Lakes, NJ, USA) on formalin-fixed, paraffin-embedded
tumour tissue as described previously (Hulsebos et al, 2007).
RESULTS
Mutation analysis of INI1
Sequencing of the 9 INI1-exons and their flanking sequences in the
constitutional blood DNA of patient III-1 revealed a mutation in
the donor splice site of exon 4 (Figure 2). This heterozygous G4A
mutation alters the conserved GT sequence at the beginning of
intron 4 (c.500þ1G4A of the mRNA (GenBank accession number
U04847)), enabling read-through of the transcript at this position.
Concomitantly, the G4A mutation results in the generation of an
in-frame stopcodon (UGG-UGA, p.W167X) in the read-through
transcript. This mutation was also present in the constitutional
DNA of patient III-4 and of the unaffected fathers II-2 and II-3.
As exemplified in Figure 2 for tumour MBT-1, the malignant brain
tumours of patients III-1(MBT-1), III-3 (MBT-3), and III-4 (MBT-4,
MBT-4R) and the myoepithelioma of patient III-1 (My-1), but
not his meningioma (M-1), showed loss of the wild-type G-allele
and retention of the mutant A-allele. Mothers II-1 and II-4 and
also grandmother I-2 had only the wild-type sequence in their
constitutional DNA (data not shown). The sequencing data for
INI1 are summarised in Figure 1. To exclude that the G4A donor
splice site mutation represents a polymorphism, we screened the
constitutional DNA of 132 normal individuals (264 chromosomes
22) by DHPLC analysis of PCR products containing the exon
4–intron 4 junction region in INI1 but found no mutation-specific
profile.
Immunohistochemical analysis of INI1 protein expression
In about 3% of cases, the normal GT donor splice site signal at the
exon 4–intron 4 junction is ignored during transcription of INI1
and splicing occurs at a cryptic splice site (GC), which is 54bp
distal to the normal splice site (GenBank accession number
AK024025) (Favre et al, 2003). Mutation of the GT donor splice site
may increase the rate of this alternative splicing. However, the
concomitant generation of a stop-codon confers the alternatively
spliced transcript in an excellent target for nonsense-mediated
decay (Nagy and Maquat, 1998), resulting in absence of INI1
protein encoded by the mutated allele. Alternatively, the mutation
may result in skipping of exon 4, generating a transcript that is 138
bases shorter than the wild-type transcript and an INI protein with
an in-frame deletion of 46 amino-acid residues. To determine the
Table 1 Clinical and histopathological features of patients with malignant brain tumour of infancy
Patient
Current diagnosis (ID in
Figure 1)
Age (years) at
diagnosis Survival (years) Location
Rhabdoid
cells
a
INI1
expression
b
III-1 AT/RT (MBT-1) 4.5 Alive and well at age 29 Fourth ventricle ++ ND
Meningothelial meningioma (M-1) 25 Left temporal   +
Myoepithelioma (My-1) 26 Upper lip   
III-2 AT/RT? 0.6 Death of disease at age 0.6 Fourth ventricle ND ND
III-3 AT/RT (MBT-3) 1.7 Death of disease at age 2.0 Right lateral
ventricle
++ ND
III-4 AT/RT (MBT-4) 0.6 Alive and well at age 16 Fourth ventricle + ND
AT/RT recurrence (MBT-4R) 2.5 Fourth ventricle +  
aPresence (+) or absence ( ) of cells with eosinophilic intracytoplasmic globules; these cells were generally vimentin and GFAP positive; additionally, the cells showed variable
EMA staining, but were desmin negative.
b+¼retention;  ¼loss; ND¼not determined (no tissue available anymore).
C C C  T TTG G T GT  GGAT
C C C  T TTG A T GT  GGAT
C C CT TTG G T GTG G A T
A 
Exon 4 Intron 4 
Normal 
Blood of III-1
MBT-1 of III-1
Figure 2 Sequence analysis of the exon 4–intron 4 boundary of INI1.
Constitutional heterozygosity for the G4A mutation in blood DNA of
patient III-1 (B) but not in normal DNA (A) and retention of the mutant
A-allele in MBT DNA of patient III-1 (MBT-1) (C).
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spresence of INI1 protein in the tumours, we performed
immunohistochemistry with an INI1-antibody on available histo-
logical sections of tumours. The antibody is directed against the
C-terminal part of the protein (amino-acid residues 257–359),
which remains intact after the eventual in-frame deletion of 46
amino-acid residues (nrs122–167) resulting from exon-4 skipping.
As shown in Figure 3, nuclear staining was absent in tumour cells
of the recurrence of the brain tumour of patient III-4 (MBT-4R)
and in the myoepithelioma of patient III-1 (My-1), but abundantly
present in all cells of the meningioma (M-1) of patient III-1. As our
sequencing data demonstrated that the normal INI1 gene was lost
in the recurrent brain tumour and in the myoepithelioma, but
remained in the meningioma, this staining pattern is consistent
with the notion that the mutant allele does not encode INI1 protein
or shortened INI1 protein as the consequence of exon-4-skipping.
Microsatellite analysis with chromosome 22 markers
Our sequencing data indicated that the normal INI1 gene was lost
in all analysed tumours, except for the meningioma. To determine
the mechanism by which these losses occurred, we extended
previously reported haplotype and LOH analyses (Hulsebos et al,
1999). The key genetic events are summarised in Figure 1. The
LOH analyses indicate that loss of the normal INI1 gene is caused
by the deletion of a complete copy of chromosome 22 in the MBTs,
but by interstitial deletion in the myoepithelioma. Furthermore,
we noted the aberrant retention of allele 1 of marker D22S929 in
the brain tumour as well as in the myoepithelioma of patient III-1
(see Figures 1 and 4). Flanking markers nf2C3.1 and nf2CAV,
however, showed normal retention of the paternal alleles in the
myoepithelioma of this patient. As the three markers are located
within the NF2 gene (Legoix et al, 1999), we investigated whether
this gene was affected by the rearrangement. Sequencing of the 17
exons of NF2 in constitutional, meningioma, and myoepithelioma
DNA of patient III-1 revealed no mutations. Multiple ligation-
dependent probe amplification analysis of the NF2 gene demon-
strated no additional copy number aberrations in blood or
tumours of this patient (data not shown).
DISCUSSION
Inheritance of the INI1-mutation
We have shown by sequence analysis that the unaffected fathers of
the patients were carriers of the germline mutation. As the paternal
grandfather’s sister died of a brain tumour at 2 years of age and
his sons transmitted the mutation, it is most likely that the
grandfather is also an unaffected carrier and that his sister
developed the brain tumour because of inheritance of the INI1-
mutation. This is also supported by the deduced haplotypes of
the grandfather’s copies of chromosome 22. This study thus
documents the inheritance of a germline INI1-mutation that
predisposes to the development of MBTs at young age in three
subsequent generations of a family. Inheritance of an INI1-mutation
via asymptomatic carriers has been reported before in two other
families with childhood brain tumours (Taylor et al, 2000; Janson
et al, 2006). Although the analyses of the latter families suggested
that the asymptomatic transmission of the INI1-mutation exclu-
sively occurred via female carriers, it is clear from our family that
the transmission can as well take place via healthy male carriers.
Malignant brain tumours are AT/RTs
Originally, based on their (immuno)histological, ultrastructural,
and clinical characteristics, the MBTs of the patients in our family
were classified as anaplastic ependymomas (Nijssen et al, 1994).
Here, we demonstrate the biallelic inactivation by mutation and
deletion of INI1 in the MBTs of patients III-1, III-3, and III-4 and
the absence of INI1-protein expression in the recurrence of patient
III-4 (Figures 2 and 3, respectively). INI1 mutations have not been
described in ependymomas (Sevenet et al, 1999a; Kraus et al, 2001;
Weber et al, 2001), whereas biallelic inactivation of INI1 and loss of
INI1 protein expression are characteristic features of AT/RTs
(Versteege et al, 1998; Judkins et al, 2004; Biegel, 2006). Moreover,
re-evaluation revealed rhabdoid cells in histological sections of the
brain tumours (Table 1). Our data thus show that the brain
tumours in at least three of the four cousins are in fact AT/RTs.
Especially, as correct histopathological classification of paediatric
AC B
Figure 3 Immunohistochemical INI1-staining of the recurrent MBT of patient III-4 (MBT-4R) (A) and the meningioma (M-1) (B) and myoepithelioma
(My-1) (C) of patient III-1. Note absence of nuclear staining of tumour cells in MBT-4R and myoepithelioma. In contrast, the nuclei of endothelial cells of the
blood vessels in both tumours and the nuclei of all cells in the meningioma show unequivocal staining. Original magnification  200.
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Figure 4 Microsatellite analysis with intragenic NF2 markers nf2C3.1 (A)
D22S929 (B) and nf2CAV (C) of constitutional DNAs of patient III-1,
mother II-1, and father II-2, and of tumour DNAs of patient III-1. Positions
of alleles are indicated on the left. MBT-1, M-1, and My-1 represent
retained alleles in the MBT, meningioma, and myoepithelioma of patient
III-1, respectively.
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sbrain tumours can be challenging (Judkins et al, 2005; Haberler
et al, 2006), our present findings suggest that testing for the
mutational status of INI1 is warranted to exclude rhabdoid tumour
predisposition syndrome (RTPS) in previous (Dimopoulos et al,
2006) and future reports on familial ependymoma.
INI1 inactivation in the tumours of patient III-1
Patient III-1 developed an intracranial meningioma and a
myoepithelioma of the upper lip, respectively, 21 and 22 years
after operation and chemo- and radiotherapy for the AT/RT.
The meningioma had no mutation in the NF2 gene and
displayed a complex karyotype, as evidenced by single-nucleotide
polymorphism analysis, including extensive losses on chromosome
arm 1p, but no loss of chromosome 22 (data not shown). These
molecular and also the clinical characteristics of the meningioma
strongly suggest that the development of this tumour is radiation-
induced and not part of the RTPS. The biallelic inactivation of INI1
and loss of INI1 protein-expression in the myoepithelioma is
remarkable. This benign tumour type is generally characterised by
a paucity of genetic alterations and involvement of chromosome 22
or INI1 in the development of this tumour has never been reported
before (Hungermann et al, 2002).
NF2 rearrangement in the tumours of patient III-1
Another remarkable finding is the aberrant retention of the
maternal allele 1 of marker D22S929 in NF2 on the paternal copy of
chromosome 22 that remained in the AT/RT as well as in the
myoepithelioma of patient III-1 (Figures 1 and 4). This might be
explained by assuming a somatic double recombination (or gene
conversion) event in a common precursor cell for both tumours,
substituting allele 2 for allele 1 on the paternally derived
chromosome 22. Although we were unable to demonstrate that
the recombination event directly affected the coding regions of NF2,
we nevertheless conclude that both tumours must have a common
origin. Several patients with a constitutional INI1 mutation and with
two tumours at different sites have been reported (Sevenet et al,
1999b; Savla et al, 2000; Kusafuka et al, 2004; Biegel, 2006; Giunti
et al, 2006; Meyers et al, 2006). It will be of interest to determine
whether the tumours of these patients, like those of patient III-1, are
primary tumours, share somatic changes in the genome, and
originate from a common precursor cell as well.
In conclusion, we have documented the variable expression and
incomplete penetrance of an INI1 germline mutation in a third
multigeneration family with the RTPS (Wesseling et al, 2007).
Inheritance of the mutation resulted in the development early in
life of an AT/RT in at least three cousins. Two of these patients
survived this tumour for over 15 years and one of these developed
a (probably radiation induced) meningioma and a myoepithelioma
in adulthood. We recently showed (Hulsebos et al, 2007) that INI1
is a predisposing gene in familial schwannomatosis, a disorder
in which patients develop multiple schwannomas later in life and
that is also characterised by variable expression and incomplete
penetrance (MacCollin et al, 2003). It has been hypothesised that
in patients with a germline INI1 mutation, a developmental
window exists at young age in which most rhabdoid tumours occur
(Janson et al, 2006). Carriers of the INI1 mutation that do not
develop such a tumour at young age might be at increased risk of
developing other INI1-related, but not necessarily malignant
tumours later in life.
Given the small number of splice site mutations in malignant
rhabdoid tumours reported to date (Biegel, 2006), it is interesting
to note that our family and one other multigeneration family with
RTPS (Taylor et al, 2000) demonstrate an INI1 mutation at a splice
site, raising the possibility that carriers of such a mutation may
be less likely to be affected. In case of our family, there is the
additional possibility that in the brain of the unaffected carriers
alternative splicing of the INI1-mutant allele transcript, leading to
absence of INI1 protein in the brain tumours of the patients, does
not occur. Instead, skipping of exon 4, resulting in the in-frame
deletion of 46 amino-acid residues in the INI1 protein, may occur.
This truncated protein may still be (partly) functional, at least not
contributing to the development of brain tumours in these
carriers. Finally, whereas long-term survival in children with
AT/RT is extremely rare (Tekautz et al, 2005; Squire et al, 2007),
two of the four cousins we described survive for more than 15
years now. More multigeneration families with the RTPS need to
be investigated to further elucidate genotype–phenotype correla-
tions in this syndrome.
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